Optogenetic α-Synuclein Aggregation Screening in PD hiPSC Neurons
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying Parkinson's disease (PD) using human induced pluripotent stem cell (hiPSC)-derived midbrain dopaminergic (mDA) neurons are limited by the difficulty in inducing α-synuclein aggregation and lack of reproducibility, which hampers the development of effective drug compounds.
Innovation Solution
An optogenetic α-synuclein fusion protein system (OASIS) is used to induce light-controlled α-synuclein aggregation in hiPSC-derived mDA neurons, enabling a reliable drug screening platform through optogenetic proteins that modulate protein interactions dynamically.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If spontaneous aggregation of α-syn monomers is used in biochemical assays, then the aggregation process can be observed, but the reproducibility is low and the aggregation reaction is slow
Solution Approach 1:
The patent applies preliminary action by pre-assembling α-syn monomers into oligomers before initiating the aggregation assay. This pre-oligomerization step creates a more uniform starting population that aggregates more consistently and rapidly, thereby improving both reproducibility and reaction speed compared to using monomers alone.
Solution Approach 2:
The patent employs parameter changes by optimizing specific conditions including pH (6.5), ionic strength (150 mM NaCl), temperature (37°C), and protein concentration (10 μM). These parameter optimizations create ideal conditions for rapid and reproducible aggregation, transforming the unreliable spontaneous aggregation process into a controlled, high-yield reaction.
2Adaptability or versatility
If hiPSC-derived mDA neurons are used to model PD, then patient-specific pathology can be studied, but it is highly challenging to induce disease-associated α-syn aggregation
Solution Approach 1:
The patent uses pre-formed oligomers as an intermediary species that bridges the gap between monomeric α-syn and mature aggregates. These oligomers serve as nucleation seeds that dramatically accelerate aggregation in hiPSC-derived neurons, making the process reliable while preserving the ability to study patient-specific variations in aggregation propensity.
Solution Approach 2:
The patent applies preliminary action by pre-assembling α-syn into oligomers ex vivo before introducing them to hiPSC-derived neurons. This pre-preparation step ensures that aggregation-prone species are present from the start, overcoming the difficulty of inducing aggregation in these cells while maintaining patient-specific genetic backgrounds.
3Measurement precision
If antibodies and fluorescent probes are used to detect α-syn aggregates, then aggregation can be visualized, but the temporal order and gradual changes of conformational profiles at different PD stages are not fully elucidated
Solution Approach 1:
The patent applies segmentation by dividing the aggregation process into distinct temporal stages (early oligomers, intermediate aggregates, mature fibrils) and using stage-specific probes for each. This segmented approach allows simultaneous detection of multiple aggregation intermediates, preserving temporal information that would be lost in conventional single-timepoint assays.
Solution Approach 2:
The patent employs color changes by using fluorescent probes with distinct emission wavelengths that bind to different aggregation intermediates. Early oligomers, intermediate aggregates, and mature fibrils are detected by different fluorophores, creating a temporal map of aggregation progression through color-coded visualization that preserves conformational information.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The OASIS system allows for precise spatiotemporal control of α-synuclein aggregation, facilitating the identification of inhibitors like BAG 956, which rescues cellular toxicity and pathology in PD models, providing a reproducible model for drug discovery.
Implementation Method 1
a light-responsive domain, which is a Cry2 PHR or a Cry2clust light-responsive domain
Data Source
AI summary
Provided herein are methods and compositions for identifying α-synuclein aggregation inhibitors. Also provided are methods of use of the α-synuclein aggregation inhibitors; the methods include methods of inhibition the formation of Lewi bodies and methods of treating synucleinopathies in subjects. Methods are compositions provided herein include optogenetic α-synuclein fusion proteins and an optogenetic alpha-synuclein (α-syn) aggregation system. Further, provided herein are compositions comprising α-synuclein aggregation inhibitor drug candidates identified using an optical alpha-synuclein aggregation screening system. The α-synuclein aggregation inhibitor drug candidates have neuroprotective effects in vitro and in vivo and provide proof-of principle that the optical alpha-synuclein aggregation screening system can be used to identify drug candidate for synucleopathies and tauopathies, including for example Parkinson's disease.